Study on marker and control of cancer sarcopenia

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K10788
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59010:Rehabilitation science-related
• Research Institution: Nara Medical University
• Principal Investigator: Fujii Kiyomu 奈良県立医科大学, 医学部, 研究員 (60284189)
• Co-Investigator(Kenkyū-buntansha): 國安 弘基 奈良県立医科大学, 医学部, 教授 (00253055) ; 羅 奕 奈良県立医科大学, 医学部, 研究員 (30633797) ; 川原 勲 奈良県立医科大学, 医学部, 研究員 (80524975)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: がん性サルコペニア / HMGB1 / 中鎖脂肪酸 / 炎症性サイトカイン / 悪液質

Outline of Final Research Achievements

In this study, we elucidated the mechanism of HMGB1 inducing sarcopenia in cancer sarcopenia and showed that it is useful as a blood marker for cancer sarcopenia in human patients. Furthermore, we found that HMGB1 was reduced by dietary intervention with medium-chain fatty acids and reduced cancer sarcopenia. For these reasons, measuring blood HMGB1 in cancer patients is effective in predicting and evaluating the degree of cancer sarcopenia. It has been also suggested that control of HMGB1 by dietary intervention leads to prevention and improvement of cancer sarcopenia.

Free Research Field

リハビリテーション医学

Academic Significance and Societal Importance of the Research Achievements

本研究で示唆されたHMGB1によるがん性サルコペニアの予測・評価はがん性サルコペニアを簡便に評価・治療することを可能にする。さらに、中鎖脂肪酸という栄養成分を用いた食事介入がHMGB1を制御できることは、簡便かつ低価格ながん性サルコペニアの予防・改善をもたらす。今後の臨床応用が期待される。